The Protocol Review and Monitoring System (PRMS) of the Indiana University Simon Cancer Center (IUSCC) provides internal oversight of all cancer clinical trials of the IUSCC. The PRMS is the shared responsibility of two committees: 1. The IUSCC Scientific Review Committee (SRC) chaired by Dr. James Croop: The SRC evaluates the scientific merit of all cancer-related clinical trials proposed by Indiana University School of Medicine faculty or faculty of other IU schools who require Cancer Center resources, including patients or tissues, for conduct of a clinical trial. It assures that the disease-oriented groups and the Principal Investigator (PI) have appropriately prioritized the trial relative to the availability of patients and research staff. The SRC is also responsible for the "scoring" of protocols seeking support from the IUSCC "Protocol Specific Research" mechanism. 2. The IUSCC Clinical Trials Monitoring Committee (CTMC) chaired by Dr. Romnee Clark: The primary responsibilities of the CTMC are to assess the adequacy of trial-specific data safety monitoring plans (DMSP's) for each protocol reviewed by the SRC, to review IUSCCsponsored studies for patient safety, to ensure protocol and adverse event report compliance, and to conduct internal audits and quality assurance reviews. In this section we will discuss the function of the Scientific Review Committee. The activities of the Clinical Trials Monitoring Committee will be discussed in the Data and Safety Monitoring section. The Clinical Research Committee (CRC) chaired by Dr. Kathy Miller, Interim Associate Director for Clinical Research, oversees the policies and procedures of the SRC and CTMC, receives monthly reports of the activities of these committees, and arbitrates in the event of disputes. An investigator may request informal consultation from the SRC prior to submission of the proposal. Investigators also may seek assistance from a protocol development coordinator for help with protocol development and SRC submission. There are also a variety of protocol templates available on the Cancer Center intranet. After submission, the SRC reviews the protocol document. At the time of the initial review, the CTMC chair evaluates the adequacy of the protocol-specific DSMP, After review, an investigator may meet with a member of the SRC and/or a Cancer Center biostatistician for further guidance. Once a protocol has been approved by the SRC, it is submitted for Institutional Review Board (IRB) review. The IRB receives a copy of the SRC review. No trial can be submitted to the Indiana University-Purdue University at Indianapolis (IUPUI) IRB without prior review by the SRC. The conduct of activated investigator-initiated protocols is monitored by the CTMC (described in the Data and Safety Monitoring section). In the event of significant toxicity and/or protocol regulatory non-compliance, the CTMC chair notifies both the investigator and the CRC of its findings and recommendations. In addition, the CTMC informs the IRB of its findings and recommendations. The CRC reviews and approves the recommendations. In the event of a serious breach of Good Clinical Practice (GCP), the CRC will notify the Director of the IU Simon Cancer Center, who will take appropriate action. It must be emphasized that it is an absolute requirement of the Schools of Medicine and Nursing, as articulated by Deans Craig Brater and Marion Broome, that all cancer clinical or behavioral trials that either are proposed by IU faculty members or proposed by others and that seek the use of IU Simon Cancer Center patients or resources must be submitted for review by the SRC. These protocols must be reviewed and approved by the SRC prior to IRB submission. The IRB will not review cancer trials until they have been approved by the SRC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA082709-14S3
Application #
8637215
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-09-22
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
14
Fiscal Year
2013
Total Cost
$82,641
Indirect Cost
$29,666
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Broxmeyer, Hal E; Pelus, Louis M (2014) Inhibition of DPP4/CD26 and dmPGE? treatment enhances engraftment of mouse bone marrow hematopoietic stem cells. Blood Cells Mol Dis 53:34-8
Blue, Emily K; DiGiuseppe, Robert; Derr-Yellin, Ethel et al. (2014) Gestational diabetes induces alterations in the function of neonatal endothelial colony-forming cells. Pediatr Res 75:266-72
Miller, Kathy D; Althouse, Sandra K; Nabell, Lisle et al. (2014) A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. Breast Cancer Res Treat 148:99-106
Chiorean, E Gabriela; Schneider, Bryan P; Akisik, Fatih M et al. (2014) Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 89:284-91
Nudelman, Kelly N H; Wang, Yang; McDonald, Brenna C et al. (2014) Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One 9:e96713
Hocevar, Barbara A; Kamendulis, Lisa M; Pu, Xinzhu et al. (2014) Contribution of environment and genetics to pancreatic cancer susceptibility. PLoS One 9:e90052
Chitteti, Brahmananda Reddy; Kobayashi, Michihiro; Cheng, Yinghua et al. (2014) CD166 regulates human and murine hematopoietic stem cells and the hematopoietic niche. Blood 124:519-29
Chitteti, Brahmananda Reddy; Srour, Edward F (2014) Cell cycle measurement of mouse hematopoietic stem/progenitor cells. Methods Mol Biol 1185:65-78
Chang, Hua-Chen; Lewis, David; Tung, Chun-Yu et al. (2014) Soypeptide lunasin in cytokine immunotherapy for lymphoma. Cancer Immunol Immunother 63:283-95
Speth, Jennifer M; Hoggatt, Jonathan; Singh, Pratibha et al. (2014) Pharmacologic increase in HIF1* enhances hematopoietic stem and progenitor homing and engraftment. Blood 123:203-7

Showing the most recent 10 out of 83 publications